



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

HAND ONE CONTOURNED.
10/050,200
January 16, 2002
Anne M. Fourie
1652
Walicka
ORT-1417

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² Cite Examiner where relevant passages of Cited Document of Cited Document initiats Number (If known) or relevant figures appear No.1 mm-dd-yyyy M 5,981,200 Tsien et al. 11/09/1999

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Exeminer Cite passages or relevant mm-dd-yyyy T **Applicant of Cited Document** Initials figures appear Office³ Number KindCode⁵ No.5 iMMWQ 02/20011 A2 Ortho McNell Pharmaceutical, Inc. 14 March 2002

			· · · · · · · · · · · · · · · · · · ·
Examiner	M. C. 1 11	Date	10/04/04
Signature	M'estidle	Considered	10/24/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

: Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

S CONSCIDEN OF KULDULUSIDEN AUSERS IS A PARAMENT	a valu onto conto number.	
Application Number	10/050,200	
Filing Date	January 18, 202	
First Named Inventor	FOURIE. et. al.	
Group Art Unit	1646	
Examiner Name		
Attorney Docket Number	ORT-1417	

U.S. PATENT DOCUMENTS							
		U.S. Patent Do	ocument .	Mary A Datasta and Applicant	Date of Publication	Pages, Columns, Lines,	
Examiner Initials		Number	Kind Code* (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	
·							
	1						
	 						
						-	
		<u> </u>					
				· · · · · · · · · · · · · · · · · · ·			

	Foreign Patent Document Date of Publica			Foreign Patent Document		Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number ⁴ Ki	ndCode ³	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Τ°
W		WO	00/05256	A1	DU PONT PHARMACEUTICALS COMPANY	02/03/2000		
-								

Examiner	Modridle	Date (() (14(1)/1
Signature	on on one	Considered	27/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, e Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

CO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20221

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Palen and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1996, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays t	a valid Civili control number.
Application Number	10,050,200
Filing Date	January 18, 2002
First Named Inventor	FOURIE, et. al.
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	ORT-1417

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
dh	140.	ABBASZADE, I., et. al., "Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family", The Journal of Biological Chemistry, 1999 Vol 274(33):23443-23450.	
dv	•	BAILEY, S., et al., "Selective Inhibition of Low Affinity IgE Receptor (CD23) Processing: P1' Bicyclomethyl Substituents," Bicorganic & Medicinal Chemistry Letters 1999 9:3165-3170.	····
JW	-	CATERSON, B., et. al., "Mechanisms involved in cartilage proteoglycan catabolism," Matrix Biology 2000 19:333-344.	
W	•	CHEN, J., et. al., "Design, Synthesis, Activity, And Structure Of A Novel Class Of Matrix Metalloproteinase Inhibitors Containing A Heterocyclic P2'-P3' Amide Bond Isostere," Bioorganic & Medicinal Chemistry Letters, 1998 Vol 6(13):1601-1608	
lW	-	HORBER, C., et. al., "Truncation of the amino-terminus of the recombinant aggrecan rAgg1(mut) leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions." Matrix Biology 2000 19:533-543.	
W	:	LOHMANDER, L. S., et al., "The Structure of Aggrecan Fragments in Human Synovial Huld," Arthritis & Rheumatism, 1993 36(9):1214 1222	
MY	١	PRATTA, M., et. al., "Age-related Changes in Aggrecan Glycosylation Affect Cleavage by Aggrecanase," Journal of Biological Chemistry, 2000 Vol. 275(50):39096-39102.	
W	•	PRIMAKOFF, P., and MYLES, D. G., "The Adam gene family surface proteins with adhesion and protease activity." Trends Genet 2000 16(2):83-87	
M	•	ROGHANI, M., et. al., "Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity," Journal of Biological Chemistry, 1999 Vol 274(8):3531-3540.	·
dw	•	SANDY, J.D., et. al., "The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1," Biochemistry Journal 2000 351:161-166	
dw	•	TANG, B. L., and Hong, W., "ADAMTS: A novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats." FEBS Letters 445:223-225 1999	
dW	•	TORTORELLA, M. D., et. al., "Sites of Aggrecan Cleavage by Recombinant Human Aggrecanase-1 (ADAMTS-4)," Journal of Biological Chemistry 2000 Vol. 275(24):18566-18573.	
W	`	TORTORELLA, M. D., et. al., "Purification and Cloning of Aggrecanase-1: A Member of the ADAMTS Family of Proteins," 1999 Vol 284:1664-1666	
W	•	Medline 98403880, 1998	
W	•	Medline 99367476, 1999	
•			

Examiner	14/01 (1/2	Date	iolou(0)
Signature	morticus	Considered	10124104

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the incividual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office. Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.